{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T09:17:18Z","timestamp":1777972638277,"version":"3.51.4"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Darunavir\u2010based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and\/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir\/Emtricitabine\/Tenofovir alafenamide (B\/F\/TAF) in these populations despite limited real\u2010world outcome data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single centre, retrospective analysis of virological outcomes in individuals previously treated with Darunavir who initiated B\/F\/TAF before 01\/01\/2025. Logistic regression was used to analyse associations with sustained virological suppression (HIV RNA &lt;200 copies\/mL) on B\/F\/TAF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 223 individuals who initiated B\/F\/TAF, 207 (median age 52 [40\u201358] years, 38% female, 69% Black ethnicity, 24% with CD4\u2009&lt;\u2009200 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      and 36% with HIV RNA \u2265200 copies\/mL) contributed virological outcome data. Over a median of 2.4 [1.3\u20133.3] years, 153 (74%) maintained or achieved sustained virological suppression, 11 (5.3%) had a single viral load \u2265200 copies\/mL and 43 (20.8%) experienced virological failure. Participants with CD4\u2009&lt;\u2009200 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      (aOR 0.15 [95%CI 0.07\u20130.33]) and HIV RNA \u2265200 copies\/mL (aOR 0.17 [0.08\u20130.34]) at B\/F\/TAF initiation were less likely to achieve sustained virological suppression; historical resistance\u2010associated mutations (RAMs) were not associated with virological outcome. Of the 32 participants successfully genotyped, 3 had novel INSTI mutations (E157Q, L74LM) and 4 had not previously documented NRTI mutations (M184V\/I, D67DN, Y115F) mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Substituting of Darunavir\u2010based ART with B\/F\/TAF in this challenging population was associated with treatment\u2010emergent INSTI and NRTI resistance. Historical resistance did not predict virological outcomes and treatment\u2010emergent resistance did not preclude re\u2010suppression on B\/F\/TAF, suggesting that adherence remains a major barrier to achieving long\u2010term virological success.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70204","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T03:50:49Z","timestamp":1770004249000},"page":"803-808","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Virological outcomes with\n                    <scp>Bictegravir\/Emtricitabine\/Tenofovir<\/scp>\n                    alafenamide (\n                    <scp>B\/F\/TAF<\/scp>\n                    ) in people previously treated with darunavir\u2010based antiretroviral therapy"],"prefix":"10.1111","volume":"27","author":[{"given":"Rhianna","family":"Sheridan","sequence":"first","affiliation":[{"name":"King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin","family":"Osei\u2010Kuffour Ekert","sequence":"additional","affiliation":[{"name":"King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Campbell","sequence":"additional","affiliation":[{"name":"King's College Hospital NHS Foundation Trust  London UK"},{"name":"King's College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Hawkins","sequence":"additional","affiliation":[{"name":"King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Childs","sequence":"additional","affiliation":[{"name":"King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2844-1612","authenticated-orcid":false,"given":"Frank A.","family":"Post","sequence":"additional","affiliation":[{"name":"King's College Hospital NHS Foundation Trust  London UK"},{"name":"King's College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13446"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00092-3"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30036-2"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101991"},{"key":"e_1_2_7_6_1","article-title":"Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open\u2010label, non\u2010inferiority trial","author":"Behrens GMN","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2025.2456890"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf087"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae377"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-025-02648-3"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003749"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13376"},{"key":"e_1_2_7_13_1","unstructured":"HIVdb Program: Mutations AnalysisAvailable from:https:\/\/hivdb.stanford.edu\/hivdb\/by-patterns\/."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae085"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab297"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13520"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104717"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106039"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae560"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70204","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70204","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:50:35Z","timestamp":1777971035000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/hiv.70204"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70204","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"assertion":[{"value":"2025-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}